Antibodies
4 April 2012
UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis2 April 2012
Lilly Targets Faulty c-MET Receptor in Cancer Research Studies Presented Today at AACR Meeting2 April 2012
Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer31 March 2012
ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate30 March 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer27 March 2012
Morphotek, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian Cancer26 March 2012
Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody26 March 2012
Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs24 March 2012
Daiichi Sankyo Files for Approval in Japan to Market AMG 162 (denosumab), a Treatment for Osteoporosis21 March 2012
Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 AntibodyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports